News
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
Today, CADTH has issued final recommendations for:
Enasidenib (Idhifa) for Acute Myeloid Leukemia
Funding Request: For the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation
Recommendation: Do not reimburse
Notification to implement target date: November...
Today, CADTH has issued final recommendations for:
insulin degludec + liraglutide (Xultophy)
Indications: Diabetes mellitus, Type 2
Recommendation: Reimburse with clinical criteria and/or conditions
For more information
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
TBC
Generic name
semaglutide
Manufacturer
Novo Nordisk Canada Inc.
Indication(s)
diabetes mellitus, type 2
Project Number
SR0637-000
Call for patient input
2019-10-24
Patient input...
Today, CADTH has issued final recommendations for:
onabotulinumtoxinA (Botox)
Indications: Migraine, chronic
Recommendation: Reimburse with clinical criteria and/or conditions
For more information
